Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients based on induction chemotherapy response

Nasopharyngeal carcinoma (NPC) is an endemic malignancy in South China [1]. Based on its epidemiology and biological characteristics, NPC is different from other head and neck cancers [2]. Cisplatin-based concurrent chemoradiotherapy (CCRT) has been established as the standard treatment regimen for local advanced NPC patients [3,4]. Recently, the application of induction chemotherapy (IC) before CCRT has received considerable attention. According to previous studies, IC plays an important role in decreasing risk of distant metastasis and improving clinical outcomes [5 –7].

Source: Radiotherapy and Oncology - May 8, 2019 Category: Radiology Authors: Sai-Lan Liu, Xue-Song Sun, Jin-Jie Yan, Qiu-Yan Chen, Huan-Xin Lin, Yue-Feng Wen, Shan-Shan Guo, Li-Ting Liu, Hao-Jun Xie, Qing-Nan Tang, Yu-Jing Liang, Xiao-Yun Li, Chao Lin, Yu-Yun Du, Zhen-Chong Yang, Bei-Bei Xiao, Jin-Hao Yang, Lin-Quan Tang, Ling Guo Tags: Original Article Source Type: research